Orchestra BioMed Holdings, Inc.·4

May 20, 8:00 AM ET

Aryeh Jason 4

Research Summary

AI-generated summary

Updated

Orchestra BioMed (OBIO) Director Aryeh Jason Buys 665 Shares

What Happened
Director Aryeh Jason made an open-market purchase of 665 shares of Orchestra BioMed (OBIO) on 2026-05-18. The reported weighted-average price was $3.75 per share, for a total reported transaction value of $2,494. This was a purchase (insider buy), which investors often view as a sign of confidence, though no motive is stated.

Key Details

  • Transaction type: Purchase (Code P) — open market/private purchase on 2026-05-18.
  • Price: weighted average $3.75; actual trade prices ranged $3.75–$3.76 (footnote).
  • Total value: $2,494 (665 shares × ~$3.75).
  • Shares owned after transaction: Not specified in the provided filing data.
  • Footnote: The price is a weighted average; the filer can provide a breakdown of the number of shares at each price within the $3.75–$3.76 range upon request (Footnote F1).
  • Filing timeliness: Reported on 2026-05-20 for a 2026-05-18 transaction — appears to be timely (filed within the usual 2-business-day window).

Context
This was a small-dollar insider purchase (low hundreds of dollars). Purchases tend to attract attention from retail investors as a potential bullish signal, but the filing alone doesn’t explain intent or indicate larger strategic moves. No options exercises, awards, gifts, or tax-withholding events are reported in this transaction.